AstraZeneca Plc (LON:AZN) reveals that its diabetes drug Farxiga prevents kidney problems
- AstraZeneca Plc (LON:AZN) today announced the Phase 3 trial results for Farxiga, its diabetes drug, revealing that it minimized the likelihood of kidney function decline.
- The results of the Declare-Timi 58 trial showed that patients that have type-2 diabetes, who took Farxiga, had a 47% less chance of developing kidney complications.
The trial compared Farxiga’s impact on kidney function with that of a placebo, which yielded the above results over the trial period.
Joris Silon, an AstraZeneca senior vice-President in charge of the cardiovascular, renal and metabolism division, commented that the latest data supports previous cardio-renal results achieved by Farxiga.
Silon also pointed out that the trials were conducted on a diverse group of everyday diabetes patients.